SCHEMBL10244714

SCHEMBL10244714

CNC(=O)NCCNS(C)(=O)=O

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
EPHX2 P34913 2/20 0.35
KMT2A Q03164 2/20 0.35
MTNR1A P48039 2/20 0.34
KDM4D Q6B0I6 1/20 0.34
ALDH1A1 P00352 2/20 0.33
ALOX15 P16050 1/20 0.33
MALT1 Q9UDY8 1/20 0.33
PTGES O14684 1/20 0.33
HSD17B10 Q99714 1/20 0.32
POLB P06746 1/20 0.32
SCN9A Q15858 1/20 0.32
EPHX1 P07099 2/20 0.31
CA2 P00918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18746213 0.88 ALDH1A1 (0.37) KEAP1NFE2L2EPHX2KMT2AALDH1A1
SCHEMBL4545266 0.81 KEAP1 (0.48) KEAP1NFE2L2KMT2AMTNR1AALDH1A1
SCHEMBL19172568 0.78 KEAP1 (0.47) KEAP1NFE2L2EPHX2KMT2AMTNR1A
SCHEMBL14365950 0.78 GRIA1 (0.50) KEAP1NFE2L2KMT2AMTNR1AALDH1A1
SCHEMBL145975 0.77 KDM4D (0.39) KMT2AKDM4DALDH1A1MALT1PTGES
SCHEMBL1912202 0.77 MAPK1 (0.48) MTNR1AKDM4DALDH1A1MALT1PTGES
SCHEMBL14365951 0.76 EPHX1 (0.46) KEAP1NFE2L2KMT2AMTNR1AEPHX1
SCHEMBL23011666 0.76 KDM4D (0.35) EPHX2KMT2AKDM4DALDH1A1ALOX15
SCHEMBL5841987 0.76 KDM4D (0.35) EPHX2KMT2AKDM4DALDH1A1ALOX15
SCHEMBL21423968 0.76 LMNA (0.43) KMT2AKDM4DALDH1A1ALOX15PTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20070259855-A1 THIAZOLYL-DIHYDRO-INDAZOLE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259855-A1 THIAZOLYL-DIHYDRO-INDAZOLE ROR1, RORB, RORA KEAP1 1602/4885NFE2L2 2839/4885EPHX2 1813/4885
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 KEAP1 3364/4885NFE2L2 4579/4885EPHX2 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.